Company Overview and News

 
Freak ‘hailnado’ wreaks havoc in Queensland

2018-10-11 perthnow.com.au
A MASSIVE clean up operation is expected today after supercells packing tornado-driven hail cut a swath of devastation across southern Queensland.
SESG

 
Freak ‘hailnado’ wreaks havoc

2018-10-11 ntnews.com.au
A MASSIVE clean up operation is expected today after supercells packing tornado-driven hail cut a swath of devastation across southern Queensland.
SESG

 
Risk of avalanches in snow country after strong winds, heavy snowfall

2018-08-07 smh.com.au
Victoria's alpine country is at risk of avalanches following a combination of heavy snowfall and damaging winds that have battered the mountain ranges.
SESG

10
Intelsat And SES: All Systems 'Go'

2018-08-01 seekingalpha - 4
Since Kerrisdale's report on Intelsat and SES last month, important developments occurred that further solidify Kerrisdale's confidence in the stocks' upside potential.
SESG AMT I

 
The sharing economy index

2018-07-29 bworldonline
The “sharing economy” involves strangers sharing several services among themselves without being forced or mandated by a government to do so. They do so voluntarily, allowing suppliers to earn income for services they are willing to provide to consumers who are willing to avail of them at a price both have agreed upon.
SESG

 
Hundreds evacuated after dangerous crane threatens homes

2018-07-23 smh.com.au
Hundreds of residents have been evacuated from their homes in Melbourne's inner south-east after wild winds caused a crane to blow backwards, threatening to collapse and damage homes.
SESG

 
Wild winds: Roofs torn off, trees down, buildings damaged

2018-07-23 smh.com.au
Wild winds have ripped roofs off houses and brought down trees, damaging buildings across Melbourne and beyond with gusts reaching more than 110km/h.
SESG

 
Melbourne Express: Thursday, July 19, 2018

2018-07-18 smh.com.au
As soon as you step outside you'll notice it's very windy and there has actually been a severe weather warning issued for a lot of Victoria.
SESG

 
Wild winds of more than 100km/h as storm hits Melbourne

2018-07-17 smh.com.au
A thunderstorm front with the potential to produce winds of more than 100km/h has hit Melbourne this afternoon, damaging trees and properties and causing power outages and train delays.
SESG

 
Melbourne weather: Thick fog blankets the city, delays flights

2018-06-27 smh.com.au
A thick, low-lying fog is lingering over Melbourne with flights delayed and drivers urged to take extra care on the roads.
SESG

344
Intelsat S.A. And SES S.A.: To The Moon

2018-06-27 seekingalpha - 1
Intelsat and SES stand to benefit massively if the FCC permits them to sell access to their spectrum in order to accelerate the deployment of 5G.
SESG FOX VOD TMUS CMCSA I CHTR S T AAPL VZ QCOM INTC SBAC DIS

2
Eutelsat Won't Bid for Inmarsat, Clearing Way for EchoStar - Bloomberg

2018-06-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SATS SESG VSAT EUTLF ETCMY ISAT

 
SpaceX Launches Satellite for SES in Its 11th Mission This Year - Bloomberg

2018-06-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SESG

 
SES shares surge 12% after first-quarter earnings report

2018-04-27 marketwatch
SES SA engages in the provision of satellite and ground communications solutions. It focuses on value-added, end-to-end solutions in SES video and SES networks. The company was founded on March 1, 1985 and is headquartered in Betzdorf, Luxembourg. (See Full Profile)
SESG

 
Flooding from ex-cyclone Nora in Queensland

2018-03-25 smh.com.au
Cairns and Port Douglas are mopping up after torrential rain from ex-cyclone Nora caused flash flooding in Queensland's far north.
SESG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...